00000000星期X 00:00:00
Search
Keywords: Search scope:  
Contact Us

News

Font Size:big  middle  small

The FDA warned against taking medication for the elderly

Number of visits: Date:2010年11月29日 13:33
 FDA hopes that all atypical antipsychotics are additional boxed warning, stressed that when the labels of these drugs for the treatment of ultra-demented elderly behavioral disorders, will increase the risk of death. The council has asked all manufacturers of these drugs must add a warning box to demonstrate this dangerous, and indicate that have not ratified the drug use in the above circumstances. The FDA said that all the acceptance of such medication dementia-related behavioral disorders patients should let their health-care providers re-examine treatment programs. Drugs affected by the Bristol-Myers Squibb / Otsuka company's Abilify (Aripiprazole, aripiprazole), the Lilly company's Zyprexa (Olanzapine, olanzapine),  AstraZeneca's Seroquel (Quetiapine, quetiapine), J & J's Risperdal (Risperidone, risperidone), Novartis's Clozaril (Clozapine, clozapine), and Pfizer's Geodon (Ziprasidone, ziprasidone). Proposals also include Lilly company's Symbyax (Olanzapine plus Fluoxetine, olanzapine and fluoxetine), the drug was approved for the treatment of bipolar depression related disease onset. The use of these drugs for the treatment of elderly patients obstacles controversy has been going on for some time. Earlier this year, published in the British Medical Journal the results of a new study found, Seroquel for the treatment of patients with dementia symptoms of anxiety may increase the illness. Last March, the EU Commission with a medical products issued a warning that Zyprexa can not be recommended for the treatment of Alzheimer's disease patients.  In the United Kingdom, this proposal also extends to Risperdal (not passed on approval). FDA statement, adopted on 17 placebo controls, the use of four atypical antipsychotics (olanzapine and aripiprazole, risperidone and quetiapine) in the treatment of 5,106 cases of Alzheimer's disease patients with the results of the study analysis shows that acceptance of atypical antipsychotics is the mortality of patients treated patients receiving placebo treatment the mortality rate of about 1.6 to 1.7 times. Study analysis shows that, although the causes of death of varied, but most like and heart disease (heart failure or sudden death) or infections (pneumonia). The three types of atypical antipsychotics in each category (based on their chemical structure) in the treatment of Alzheimer's will increase the mortality rate, the FDA has decided to extend the application of a warning to all of these medicines. The FDA claims that may affect all atypical drugs (not including the treatment of Alzheimer's disease to study drug) common pharmacological effects related. FDA also is considering the older antipsychotics add warning labels because of limited data suggested that these drugs can also lead to increased mortality similar. However, for these older drugs information retrial is still in progress

TypeInfo: Dynamic Industry

Keywords for the information: